États-Unis · Bourse & Finance · Morningstar

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

Publié par Morningstar · États-Unis il y a 12 h

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, will present Phase II clinical data on its Nectin-4-targeting…

Lire l'article complet sur Morningstar Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

À lire aussi

Ukraine is making anti-Shahed missiles that have to cost less than $20,000 per shot

Zoom adds ‘proof of human’ badges to show you’re not a deepfake

Japanese Prime Minister Takaichi rejects criticism around weak yen and high interest rates

Oil Prices Slip as Trump-Putin Diesel Deal Raises Supply Hopes

Zcash developers plan a fix to keep ZEC swaps private from future quantum computers

China’s economy grew 4.5% last quarter, yet its export boom risks being ‘a drag on world growth’

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

Partager

À lire aussi

Ukraine is making anti-Shahed missiles that have to cost less than $20,000 per shot

Zoom adds ‘proof of human’ badges to show you’re not a deepfake

Japanese Prime Minister Takaichi rejects criticism around weak yen and high interest rates

Oil Prices Slip as Trump-Putin Diesel Deal Raises Supply Hopes

Zcash developers plan a fix to keep ZEC swaps private from future quantum computers

China’s economy grew 4.5% last quarter, yet its export boom risks being ‘a drag on world growth’